UPDATE 2-Seattle Genetics slumps as cancer drug data fails to impress
June 26, 2017 at 12:36 PM EDT
* Investors focus on narrow drug benefits vs standard of care
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.